MiRNA-375 inhibits retinoblastoma progression through targeting ERBB2 and inhibiting MAPK1/MAPK3 signalling pathway

CONCLUSIONS: MiR-375 inhibited RB progression through targeting ERBB2 and suppressing MAPK1/MAPK3 signalling pathway, which might be a new target for the clinical treatment strategy.PMID:34711123 | DOI:10.1080/15569527.2021.1994587
Source: Cutaneous and Ocular Toxicology - Category: Toxicology Authors: Source Type: research